Care and treatment

With the development of the first new anti-TB drugs (i.e. bedaquiline, delamanid and pretomanid) for many decades and the re-purposing of existing drugs to treat DR-TB patients (e.g. clofazimine, fluoroquinolones and linezolid), we are now moving into the era when patients can be offered shorter and all oral treatment regimens for DR-TB, with fewer drugs. Hence the World Health Organization (WHO) is now recommending the use of injection free i.e. all oral, shorter treatment regimens (possibly of only six to nine months duration) for various forms of DR-TB. This is a huge step forwards for patients.

KNCV believes in patient-centered care, and is currently technically supporting ten countries to implement the newly recommended six to nine months, all-oral 4-drug, BPaL regimen to improve adherence and treatment success in a specific group of DR-TB patients. Currently WHO recommends that the so-called BPaL regimen be implemented under operational research (OR) conditions. Hence KNCV is providing the countries with the wide range of technical assistance to the ten countries required to introduce the BPaL regimen under OR conditions. This includes assistance to develop implementation plans, OR protocols, and training material, assessments of facility’s readiness to introduce the novel regimen, and introduction of the necessary active drug safety and monitoring systems and recording and reporting systems. Using the expert consultant team within KNCV, these activities are being supported via the KNCV Endowment Fund in Nigeria, TB REACH Wave 7 projects in Tajikistan and Ukraine, and under the TB Alliance / KOICA’s LIFT-TB project in seven countries (Indonesia, Kyrgyzstan, Myanmar, The Philippines, Ukraine, Uzbekistan and Vietnam).

KNCV has been fighting TB since its establishment in 1903. Over the past 117 years, the organization has acquired indispensable knowledge and experience in the field of effective TB control, resulting in pre-elimination in the Netherlands and significant contributions to global evidence generation, policy development and TB program implementation worldwide.

Our experts
KNCV governance framework
Our patroness
Partner with us

Tuberculosis is still one of the major causes of preventable death in the world and claims over 4000 lives a day, leading to over 1,5 million deaths a year.

Patient stories

The story of Abdurahim
The story of Fikeraddis
The story of Issayas
The story of Zarina
The story of Maxine
The story of Saanvi

Annual Report Summary 2019
KNCV 2-pager ASCENT
KNCV 2-pager Childhood TB
KNCV 2-pager Digital Health
KNCV 2-pager General
KNCV 2pager Right Diagnosis, Right Treatment
KNCV 2-pager TB Photovoices
KNCV 2-pager TB Stigma

Sorry

De versie van de browser die je gebruikt is verouderd en wordt niet ondersteund.
Upgrade je browser om de website optimaal te gebruiken.